Loading...
| A03755 | Pages: NA | Dec 2021 | 4488 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Global Duchenne Muscular Dystrophy Therapeutics Market
Request Now !Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, low rate of treatment due to delayed diagnosis and prediction hinder the market growth. Moreover, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
The global Duchenne muscular dystrophy therapeutics market is segmented on the basis of type, end user, and region. On the basis of type, it is bifurcated into pain management drugs and corticosteroids. Corticosteroids are further sub-segmented into prednisolone, prednisone, and deflazacort. On the basis of end-user, it is divided into hospitals, clinics, and home care settings. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Key players in the market include Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc., Pfizer Inc., ReveraGen BioPharma, Inc., Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET, BY TREATMENT TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PAIN MANAGEMENT DRUDS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. CORTECOSTEROIDS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.3.1. Prednisolone
4.3.3.1.1. Market Size and Forecast
4.3.3.2. Prednisone
4.3.3.2.1. Market Size and Forecast
4.3.3.3. Deflazacort
4.3.3.3.1. Market Size and Forecast
CHAPTER 5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET, BY END USER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITALS
5.2.1. Market size and forecast
5.3. CLINICS
5.3.1. Market size and forecast
5.4. HOME CARE SETTINGS
5.4.1. Market size and forecast
CHAPTER 6 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.2.5. North America Duchenne Muscular Dystrophy Therapeutics Market, by End User
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.3.5. Europe Duchenne Muscular Dystrophy Therapeutics Market, by End User
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.4.5. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market, by End User
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast
6.5.4. LAMEA Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.5.5. LAMEA Duchenne Muscular Dystrophy Therapeutics Market, by End User
CHAPTER 7 COMPANY PROFILES
7.1. BRISTOL-MYERS SQUIBB COMPANY
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. FIBROGEN, INC.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. ITALFARMACO S.P.A.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. MARATHON PHARMACEUTICALS, LLC
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. NS PHARMA, INC
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. PTC THERAPEUTICS, INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. PFIZER INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. REVERAGEN BIOPHARMA, INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. SANTHERA PHARMACEUTICALS
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. SAREPTA THERAPEUTICS, INC
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
